PALO ALTO, Calif., April 17 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK), a biopharmaceutical company focused on discovering and developing drugs to treat serious diseases, today announced that it made four preclinical data presentations at the 99th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, Calif. The abstracts highlighted results from Telik's Research and Development programs.
Identification and Characterization of Novel Tyrosine Kinase Inhibitors
Targeting Vascular Endothelial Growth Factor Receptor 2 [Abstract # 1439]
Inhibition of the vascular endothelial growth factor receptor signaling
pathway with antibodies or small molecules has been proven effective as an
anti-cancer therapy. Through the use of Telik's Target-Related Affinity
Profiling (TRAP(R)) screening technology, novel inhibitors of VEGFR2
kinase were discovered. The inhibitors belong to nine structural classes,
among which E2B8 and EAAF are sub-micromolar inhibitors of the kinase.
Mechanism of Induction of Apoptosis by TLK199 (TELINTRA(R)) in Human
Leukemia Cell Lines [Abstract # 2270]
Telik researchers conducted studies with data highlighting TLK199, a novel
glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1,
which induces apoptosis, or programmed cell death, in human HL60
promyelocytic cells and TF-1 erythroleukemic cells. Treatment of the
leukemia cells with TLK199 also resulted in an increase of the
phosphorylation of eIF2alpha, a key signaling event in the integrated
stress response (ISR), and in induction of multiple genes implicated in
ISR. Telik currently has ongoing studies of T
|SOURCE Telik, Inc.|
Copyright©2008 PR Newswire.
All rights reserved